Oncology

Cilta-Cel's Efficacy in Heavily Pretreated Patients With Multiple Myeloma: Thomas G. Martin, MD

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from the CARTITUDE-1 study presented at ASH 2021.

Celularity’s CYNK-101 Wins Fast Track Designation for HER2+ Gastric/GEJ Cancers

The designation follows the approval of its IND application for the natural killer cell therapy in November 2021.

Improving Specificity of T-Cell Therapies in Solid Tumors: Julian Molina, MD, PhD : Julian Molina, MD, PhD

The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod technology in solid tumors.